Circadian rhythm sleep disorder, irregular sleep wake type

Summary

Circadian rhythm sleep disorder, irregular sleep wake type (MONDO:0024379) is a disease. A subtype of circadian rhythm sleep disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	circadian rhythm sleep disorder, irregular sleep wake type
Mondo ID	MONDO:0024379
ICD-10-CM	G47.23
SNOMED CT	271793004
UMLS	C0393771
MedGen	581571
Is cancer (heuristic)	no

Also known as: irregular sleep-wake disorder · irregular sleep-wake pattern · ISWD

Disease family

This is a subtype of circadian rhythm sleep disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › sleep disorder › sleep-wake disorder › circadian rhythm sleep disorder › circadian rhythm sleep disorder, irregular sleep wake type

Related subtypes (7): advanced sleep phase syndrome, non-24-hour sleep-wake syndrome, rapid eye movement sleep disorder, circadian rhythm sleep disorder, delayed sleep phase type, circadian rhythm sleep disorder, advanced sleep phase type, circadian rhythm sleep disorder, jet lag type, circadian rhythm sleep disorder, shift work type

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.